Ocera Therapeutics, Inc.
OCRX
OCRX was delisted on the 8th of December, 2017.
24 hedge funds and large institutions have $6.29M invested in Ocera Therapeutics, Inc. in 2017 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 8 reducing their positions, and 6 closing their positions.
8% less funds holding
Funds holding: 26 → 24 (-2)
13% less capital invested
Capital invested by funds: $7.22M → $6.29M (-$935K)
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
38% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
+$164K |
| 2 |
HP
Hikari Power
Tokyo,
Japan
|
+$147K |
| 3 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$116K |
| 4 |
ARTA
A.R.T. Advisors
New York
|
+$95.8K |
| 5 |
AWS
AJ Wealth Strategies
New York
|
+$60.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$382K |
| 2 |
PA
Perceptive Advisors
New York
|
-$129K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$73K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$39.3K |
| 5 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$36.8K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TSS
26
Two Sigma Securities
New York
| – | -$25K | -19,180 | Closed |
|
|
IIA
27
IPG Investment Advisors
San Diego,
California
| – | -$19.6K | -15,000 | Closed |
|
28
UBS Group
Zurich,
Switzerland
| – | -$10K | -7,837 | Closed |
|
|
FPF
29
FNY Partners Fund
New York
| – | -$8K | -6,400 | Closed |
|
|
TRCT
30
Tower Research Capital (TRC)
New York
| – | -$1K | -800 | Closed |
|
OCRX Hedge Fund Activity: Q2 2017 in Review
24 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Ocera Therapeutics, Inc. (OCRX) for Q2 2017, worth a combined $6.29M — down 13% from $7.22M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of OCRX and 4 opened new positions — a net loss of 2 holders — while 8 trimmed existing stakes and 5 added.
The largest buyer was Virtu KCG Holdings, adding an estimated $164K. The largest seller was Vanguard Group, cutting an estimated $382K.
- 24 institutional investors held Ocera Therapeutics, Inc. (OCRX) as of Q2 2017, down from 26 in Q1 2017.
- Funds reported $6.29M of Ocera Therapeutics, Inc. stock for Q2 2017, down 13% quarter-over-quarter.
- 4 funds opened new Ocera Therapeutics, Inc. positions in Q2 2017 and 6 closed out, a net change of -2 holders.
- The largest Ocera Therapeutics, Inc. buyer in Q2 2017 was Virtu KCG Holdings, an estimated $164K added.
- The largest Ocera Therapeutics, Inc. seller in Q2 2017 was Vanguard Group, an estimated $382K sold.
Based on aggregated 13F filings for Q2 2017.